A study testing whether a GLP-1 medicine, semaglutide, can help people with metabolic diseases lower blood sugar.

Recruiting now. Registry record last updated July 8, 2026.

Who can join: Adults 18 to 65, have metabolic diseases.
What you take: Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 3 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 4Sponsor Massachusetts General HospitalDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 125

What this study is for

Primary condition: Genetic Predisposition. Also studied in: Metabolic Diseases, Type 2 Diabetes.

Full scientific study title: GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH.

Who can join

Age18 to 65SexAny

Adults 18 to 65, have metabolic diseases. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Males or non-pregnant females
Ages 18-65 (inclusive)
Able/willing to give consent
Span the metabolic range between normal glycemia and pre-diabetes (fasting glucose of 100-125 mg/dL based on chart review of existing laboratory data)

Key exclusion criteria

Currently taking medications or intending to take medications for diabetes
Currently taking medications or intending to take medications that affect glycemic parameters, such as glucocorticoids, growth hormone, or fluoroquinolones
Personal history of intestinal malabsorption, bariatric surgery, celiac disease, gallbladder disease, or pancreatitis
Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2
Estimated glomerular filtration rate (eGFR) \<60 ml/min/1.73 m2 per the Modification of Diet in Renal Disease equation

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Massachusetts1 site

Massachusetts General Hospital
Boston, Massachusetts
Varinderpal Kaur6176435419vkaur@mgh.harvard.edu

Follow this trial

We email you if NCT06003153 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: March 12, 2024. Expected completion: May 31, 2027. Last updated on ClinicalTrials.gov: July 8, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.